This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e17 (https://www. gastrojournal.org/cme/home). Learning Objective: Upon completion of this CME activity, successful learners will be able to (1) discuss the clinical relevance of normalizing serum albumin concentration in patients with decompensated cirrhosis and ascites and (2) identify the main mechanisms of action of albumin in this setting. Effects of long-term albumin treatment on serum albumin levels and inflammatory cytokines High albumin dose (HAlbD: 1.5 g/kg every week, blue figures) but not low albumin dose (LAlbD: 1 g/kg every 2 weeks: red figures) normalized serum albumin levels and decreased inflammatory cytokines

Funding information: The AMBAR study is sponsored by Grifols, a manufacturer of therapeutic human serum albumin and intravenous immune globulin.

Supplemental Digital Content is available in the text.